Tate Group Overview
Our research lies at the interface between organic chemistry, the life sciences and medicine, in the fields of chemical biology and chemical proteomics. The unifying theme of our work is the design and application of chemical approaches to understand and manipulate living systems, with an emphasis on processes important to disease. Related to this theme, our group also undertakes research in medicinal chemistry and chemical synthesis/modification of proteins and peptides.
Please also see the main Tate Group Website for further information on:
- Group members
- Group News
- Staff, fellowship and studentship opportunities
- Research and current grants
About Prof. Ed Tate
Ed works in the Chemical Biology Section of the Department of Chemistry, and holds a Satellite Group Leader appointment at the Francis Crick Institute. He is a Fellow of both the Royal Society of Chemistry (FRSC) and the Royal Society of Biology (FRSB), and has been the recipient of three prestigious research fellowships, and research grants from the UK research councils, charity foundations, the EU and the pharmaceutical and biotech industries. He sits on the editorial advisory boards of Cell Chemical Biology, Molecular BioSystems, and the Biochemical Journal, the committee of the RSC Bioorganic Group, the ICR/Imperial Cancer Research Centre of Excellence board, and is the Director of the Imperial Centre for Drug Discovery Science. He was awarded the 2012 Wain Medal Lecture and Prize and the 2013 RSC/MedImmune Protein and Peptide Science Award in recognition of his research in chemical biology, and was elected FRSC in 2013, and FRSB in 2014. He also recevied the 2013 President and Rector's Award for Excellence in Research Supervision, the 2014 Norman Heatley Award in Chemical Biology, a 2015 CRUK Programme Foundation Award, the 2019 Sir David Cooksey Translation Prize, and the 2020 RSC Corday-Morgan Prize.
Following a B.Sc. degree in chemistry at the University of Durham, Ed undertook his Ph.D. in organic chemistry and methodology at the University of Cambridge under the guidance of Prof. Steve Ley. He then w orked for two years with Prof. Sam Zard at Ecole Polytechnique (Paris) on an 1851 Research Fellowship, on radical chemistry and natural product total synthesis. The award of a Howard Trust Research Fellowship enabled him to study molecular microbiology and the role of DNA secondary st ructure in transcriptional activation with Dr. Annie Kolb at the Pasteur Institute (Paris), and following this period of training in biological research he moved to Imperial College London to work on protein chemistry and chemical biology with Prof. Robin Leatherbarrow. In 2006 he was awarded a BBSRC David Phillips Research Fellowship; in 2010 he was appointed Senior Lecturer, promoted to Reader in Chemical Biology in 2012, and to Professor of Chemical Biology in 2014.
Ed is also co-founder of Myricx Pharma, which is a spin-out company based on NMT work started within the research group. Here, Ed is also the chairman of the scientific advisory board. In addition to this, he was also appointed to the scientific advisory board of Samsara Therapeutics Inc. in January 2022.
et al., 2021, A suite of activity-based probes to dissect the KLK activome in drug-resistant prostate cancer, Journal of the American Chemical Society, Vol:143, ISSN:0002-7863, Pages:8911-8924
et al., 2021, Photochemical probe identification of the small-molecule binding site in a mammalian membrane-bound O-acyltransferase, Angewandte Chemie - International Edition, Vol:60, ISSN:1433-7851, Pages:13542-13547
et al., 2021, Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1, Nature Chemical Biology, Vol:17, ISSN:1552-4450, Pages:776-783
et al., 2020, Correction to “Discovery of a Potent and Selective Covalent Inhibitor and Activity-Based Probe for the Deubiquitylating Enzyme UCHL1, with Antifibrotic Activity”, Journal of the American Chemical Society, Vol:142, ISSN:0002-7863, Pages:15199-15199
et al., 2020, Discovery of a potent and selective covalent inhibitor and activity-based probe for the deubiquitylating enzyme UCHL1, with anti-fibrotic activity, Journal of the American Chemical Society, Vol:142, ISSN:0002-7863, Pages:12020-12026
et al., 2020, Antibody–PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4, ACS Chemical Biology, Vol:15, ISSN:1554-8929, Pages:1306-1312
et al., 2020, D-Cycloserine destruction by alanine racemase and the limit of irreversible inhibition, Nature Chemical Biology, Vol:16, ISSN:1552-4450, Pages:686-+
et al., 2020, High-resolution snapshots of human N-myristoyltransferase in action illuminate a mechanism promoting N-terminal Lys and Gly myristoylation, Nature Communications, Vol:11, ISSN:2041-1723, Pages:1-15
et al., 2019, FSP1 is a glutathione-independent ferroptosis suppressor, Nature, Vol:575, ISSN:0028-0836, Pages:693-698
et al., 2019, Validation and invalidation of chemical probes for the human N-myristoyltransferases, Cell Chemical Biology, Vol:26, ISSN:2451-9456, Pages:892-900
et al., 2019, Dual chemical probes enable quantitative system-wide analysis of protein prenylation and prenylation dynamics, Nature Chemistry, Vol:11, ISSN:1755-4330, Pages:552-561
et al., 2019, AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis, Proceedings of the National Academy of Sciences of the United States of America, Vol:116, ISSN:0027-8424, Pages:1414-1419
et al., 2019, Whole proteome profiling of N-myristoyltransferase activity and inhibition using Sortase A, Molecular & Cellular Proteomics, Vol:18, ISSN:1535-9476, Pages:115-126
et al., 2018, Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus, Nature Chemistry, Vol:10, ISSN:1755-4330, Pages:599-606
et al., 2018, High-throughput kinetic analysis for target-directed covalent ligand discovery, Angewandte Chemie - International Edition, Vol:57, ISSN:1433-7851, Pages:5257-5261
et al., 2015, Global profiling of Huntingtin-associated protein E (HYPE)-mediated AMPylation through a chemical proteomic approach, Molecular & Cellular Proteomics, Vol:15, ISSN:1535-9484, Pages:715-725
et al., 2015, Multifunctional Reagents for Quantitative Proteome-Wide Analysis of Protein Modification in Human Cells and Dynamic Profiling of Protein Lipidation During Vertebrate Development, Angewandte Chemie-international Edition, Vol:54, ISSN:1521-3773, Pages:5948-5951
et al., 2014, Global profiling of co- and post-translationally N-myristoylated proteomes in human cells, Nature Communications, Vol:5, ISSN:2041-1723, Pages:1-13
et al., 2013, Validation of N-myristoyltransferase as an antimalarial drug target using an integrated chemical biology approach, Nature Chemistry, Vol:6, ISSN:1755-4349, Pages:112-121